Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017 (2017), Article ID 1236219, 11 pages
https://doi.org/10.1155/2017/1236219
Research Article

Role of CD8 Regulatory T Cells versus Tc1 and Tc17 Cells in the Development of Human Graft-versus-Host Disease

1Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Prolongación de Carpio y Plan de Ayala S/N, Colonia Santo Tomás, Miguel Hidalgo, 11340 Ciudad de México, Mexico
2Cátedras CONACyT, CONACyT, Avenida Insurgentes Sur 1582, Benito Juárez, Crédito Constructor, 03940 Ciudad de México, Mexico
3Departamento de Diferenciación Celular y Cáncer, FES Zaragoza, Universidad Nacional Autónoma de México, Batalla 5 de mayo S/N Esq. Fuerte de Loreto, Iztapalapa, 04650 Ciudad de México, Mexico
4Unidad Médica de Alta Especialidad, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Seris y Zaachila S/N, Col. La Raza, Ciudad de México, Mexico
5Departamento de Inmunología Médica, Escuela Superior de Medicina, Instituto Politécnico Nacional, Calle Plan de San Luis y Díaz Mirón S/N, Casco de Santo Tomas, Miguel Hidalgo, 11340 Ciudad de México, Mexico
6Laboratorios Nacionales de Servicios Experimentales, Centro de Investigación y de Estudios Avanzados, Instituto Politécnico Nacional, Av. IPN 2508, Colonia San Pedro Zacatenco, 07360 Ciudad de México, Mexico
7Hospital General, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Apartado Postal 14-878, 07001 Ciudad de México, Mexico

Correspondence should be addressed to Martha Moreno-Lafont; moc.liamg@tnofalmm

Received 21 March 2016; Revised 21 July 2016; Accepted 12 December 2016; Published 9 January 2017

Academic Editor: Moisés E. Bauer

Copyright © 2017 Adriana Gutiérrez-Hoya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Welniak, B. R. Blazar, and W. J. Murphy, “Immunobiology of allogeneic hematopoietic stem cell transplantation,” Annual Review of Immunology, vol. 25, pp. 139–170, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Ferrara and J. Levine, “A new approach to therapy for acute GVHD,” Cellular Therapy and Transplantation, vol. 1, no. 1, pp. 25–27, 2008. View at Google Scholar
  3. R. M. Saliba, M. De Lima, S. Giralt et al., “Hyperacute GVHD: risk factors, outcomes, and clinical implications,” Blood, vol. 109, no. 7, pp. 2751–2758, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Das, S. Imoto, T. Murayama et al., “Kinetic analysis of cytokine gene expression in patients with GVHD after donor lymphocyte infusion,” Bone Marrow Transplantation, vol. 27, no. 4, pp. 373–380, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. X. P. Ju, B. Xu, Z. P. Xiao et al., “Cytokine expression during acute graft-versus-host disease after allogeneic peripheral stem cell transplantation,” Bone Marrow Transplantation, vol. 35, no. 12, pp. 1179–1186, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. M. J. Carlson, M. L. West, J. M. Coghill, A. Panoskaltsis-Mortari, B. R. Blazar, and J. S. Serody, “In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations,” Blood, vol. 113, no. 6, pp. 1365–1374, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Coghill, S. Sarantopoulos, T. P. Moran, W. J. Murphy, B. R. Blazar, and J. S. Serody, “Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new,” Blood, vol. 117, no. 12, pp. 3268–3276, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. L. W. Kappel, G. L. Goldberg, C. G. King et al., “IL-17 contributes to CD4-mediated graft-versus-host disease,” Blood, vol. 113, no. 4, pp. 945–952, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Korn, E. Bettelli, M. Oukka, and V. K. Kuchroo, “IL-17 and Th17 cells,” Annual Review of Immunology, vol. 27, pp. 485–517, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. T. Bryceson and H.-G. Ljunggren, “Lymphocyte effector functions: armed for destruction?” Current Opinion in Immunology, vol. 19, no. 3, pp. 337–338, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. Z. Fehérvari and S. Sakaguchi, “CD4+ regulatory cells as a potential immunotherapy,” Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 360, no. 1461, pp. 1647–1661, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. R. K. Gershon and K. Kondo, “Cell interactions in the induction of tolerance: the role of thymic lymphocytes,” Immunology, vol. 18, no. 5, pp. 723–737, 1970. View at Google Scholar · View at Scopus
  13. L. Lu and H. Cantor, “Generation and regulation of CD8+ regulatory T cells,” Cellular & Molecular Immunology, vol. 5, no. 6, pp. 401–406, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. M. Wang and S. I. Alexander, “CD8 regulatory T cells: what's old is now new,” Immunology and Cell Biology, vol. 87, no. 3, pp. 192–193, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. S. G. Zheng, J. H. Wang, M. N. Koss, F. Quismorio Jr., J. D. Gray, and D. A. Horwitz, “CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-β suppress a stimulatory graft-versus-host disease with a lupus-like syndrome,” The Journal of Immunology, vol. 172, no. 3, pp. 1531–1539, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Chaput, S. Louafi, A. Bardier et al., “Identification of CD8+CD25+FoxP3+ suppressive T cells in colorectal cancer tissue,” Gut, vol. 58, no. 4, pp. 520–529, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. E. C. M. Zeestraten, A. Q. Van Hoesel, F. M. Speetjens et al., “FoxP3- and CD8-positive infiltrating immune cells together determine clinical outcome in colorectal cancer,” Cancer Microenvironment, vol. 6, no. 1, pp. 31–39, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. K. R. Muthu Raja, L. Kubiczkova, L. Rihova et al., “Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment,” PLoS ONE, vol. 7, no. 11, Article ID e49446, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. K. R. Muthu Raja, M. Plasil, L. Rihova, J. Pelcova, Z. Adam, and R. Hajek, “Flow cytometry-based enumeration and functional characterization of cd8 t regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment,” Cytometry Part B—Clinical Cytometry, vol. 86, no. 4, pp. 220–228, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Trinschek, F. Luessi, C. C. Gross, H. Wiendl, and H. Jonuleit, “Interferon-beta therapy of multiple sclerosis patients improves the responsiveness of t cells for immune suppression by regulatory T cells,” International Journal of Molecular Sciences, vol. 16, no. 7, pp. 16330–16346, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Frisullo, V. Nociti, R. Iorio et al., “CD8+Foxp3+ T cells in peripheral blood of relapsing-remitting multiple sclerosis patients,” Human Immunology, vol. 71, no. 5, pp. 437–441, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Bu, Y. Shen, W. L. Seeger et al., “Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8+ T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression,” Tumor Biology, vol. 37, no. 3, pp. 3949–3956, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Mahic, K. Henjum, S. Yaqub et al., “Generation of highly suppressive adaptive CD8+CD25+FoxP3+ regulatory T cells by continuous antigen stimulation,” European Journal of Immunology, vol. 38, no. 3, pp. 640–646, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. R. J. Robb, K. E. Lineburg, R. D. Kuns et al., “Identification and expansion of highly suppressive CD8+FoxP3+ regulatory T cells after experimental allogeneic bone marrow transplantation,” Blood, vol. 119, no. 24, pp. 5898–5908, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. A. J. Beres, D. Haribhai, A. C. Chadwick, P. J. Gonyo, C. B. Williams, and W. R. Drobyski, “CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity,” The Journal of Immunology, vol. 189, no. 1, pp. 464–474, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Liu, Q. Lan, L. Lu et al., “Phenotypic and functional characteristic of a newly identified CD8+Foxp3CD103+ regulatory T cells,” Journal of Molecular Cell Biology, vol. 6, no. 1, pp. 81–92, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Pierini, L. Colonna, M. Alvarez et al., “Donor requirements for regulatory T cell suppression of murine graft-versus-host disease,” The Journal of Immunology, vol. 195, no. 1, pp. 347–355, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. O. Rodríguez-Cortés, J. Vela-Ojeda, R. López-Santiago et al., “Granulocyte colony-stimulating factor produces a decrease in IFNγ and increase in IL-4 when administrated to healthy donors,” Journal of Clinical Apheresis, vol. 25, no. 4, pp. 181–187, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Nawa, T. Teshima, K. Sunami et al., “G-CSF reduces IFN-γ and IL-4 production by T cells after allogeneic stimulation by indirectly modulating monocyte function,” Bone Marrow Transplantation, vol. 25, no. 10, pp. 1035–1040, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. G. R. Hill, S. D. Olver, R. D. Kuns et al., “Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma,” Blood, vol. 116, no. 5, pp. 819–828, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. X.-Y. Zhao, L.-L. Xu, S.-Y. Lu, and X.-J. Huang, “IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation,” European Journal of Immunology, vol. 41, no. 2, pp. 514–526, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. E. S. Morris, K. P. A. MacDonald, V. Rowe et al., “Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance,” Blood, vol. 103, no. 9, pp. 3573–3581, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. S. N. Ukena, S. Velaga, L. Goudeva et al., “Human regulatory T cells of G-CSF mobilized allogeneic stem cell donors qualify for clinical application,” PLoS ONE, vol. 7, no. 12, Article ID e51644, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. M. O. Li, Y. Y. Wan, S. Sanjabi, A.-K. L. Robertson, and R. A. Flavell, “Transforming growth factor-β regulation of immune responses,” Annual Review of Immunology, vol. 24, pp. 99–146, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Deaglio, K. M. Dwyer, W. Gao et al., “Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression,” The Journal of Experimental Medicine, vol. 204, no. 6, pp. 1257–1265, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. K. M. Dwyer, S. Deaglio, W. Gao, D. Friedman, T. B. Strom, and S. C. Robson, “CD39 and control of cellular immune responses,” Purinergic Signalling, vol. 3, no. 1-2, pp. 171–180, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Gambichler, J. Pätzholz, L. Schmitz, N. Lahner, and A. Kreuter, “FOXP3+ and CD39+ regulatory T cells in subtypes of cutaneous lupus erythematosus,” Journal of the European Academy of Dermatology and Venereology, vol. 29, no. 10, pp. 1972–1977, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. A. E. C. Broers, J. W. Gratama, B. Löwenberg, and J. J. Cornelissen, “Lymphocyte recovery following allogeneic stem cell transplantation: new possibilities for improvement,” Clinical and Applied Immunology Reviews, vol. 2, no. 4-5, pp. 217–227, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. H.-Y. Lai, T.-Y. Chou, C.-H. Tzeng, and O. K.-S. Lee, “Cytokine profiles in various graft-versus-host disease target organs following hematopoietic stem cell transplantation,” Cell Transplantation, vol. 21, no. 9, pp. 2033–2045, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Gutiérrez-Hoya, R. López-Santiago, J. Vela-Ojeda, L. Montiel-Cervantes, O. Rodríguez-Cortés, and M. C. Moreno-Lafont, “Determination of Th1/Th2/Th17 cytokines in patients undergoing allogeneic hematopoietic stem cell transplantation,” in New Advances in Stem Cell Transplantation, T. Demirer, Ed., pp. 83–102, Editorial Taner Demire, Istanbul, Turkey, 2012. View at Publisher · View at Google Scholar
  41. R. Broady, J. Yu, V. Chow et al., “Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells,” Blood, vol. 116, no. 25, pp. 5748–5751, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Colonna, M. Florek, D. B. Leveson-Gower et al., “IL-17 gene ablation does not impact treg-mediated suppression of graft-versus-host disease after bone marrow transplantation,” Biology of Blood and Marrow Transplantation, vol. 19, no. 11, pp. 1557–1565, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. A. B. Van der Waart, W. J. F. M. van der Velden, N. M. Blijlevens, and H. Dolstra, “Targeting the IL17 pathway for the prevention of graft-versus-host disease,” Biology of Blood and Marrow Transplantation, vol. 20, no. 6, pp. 752–759, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Zhao, S. Ruan, L. Yin et al., “Dynamic regulation of effector IFN-γ-producing and IL-17-producing T cell subsets in the development of acute graft-versus-host disease,” Molecular Medicine Reports, vol. 13, no. 2, pp. 1395–1403, 2016. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Zheng, Y. Liu, M. Liu et al., “Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice,” Science Translational Medicine, vol. 5, no. 168, Article ID 168ra9, 2013. View at Google Scholar
  46. W. Zou, “Regulatory T cells, tumour immunity and immunotherapy,” Nature Reviews Immunology, vol. 6, no. 4, pp. 295–307, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Wang, J. Fan, S. Chen, Y. Zhang, T. J. Curiel, and B. Zhang, “Graft-versus-host disease is enhanced by selective CD73 blockade in mice,” PLoS ONE, vol. 8, no. 3, Article ID e58397, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Tsukamoto, P. Chernogorova, K. Ayata et al., “Deficiency of CD73/ecto-5′-nucleotidase in mice enhances acute graft-versus-host disease,” Blood, vol. 119, no. 19, pp. 4554–4564, 2012. View at Publisher · View at Google Scholar · View at Scopus